SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically\* confirmed Hodgkin's or non-Hodgkin's lymphoma (NHL) of any histology
• * The following NHL types are eligible:
• * Diffuse large B-cell lymphoma
• * Follicular lymphoma
• * Mantle Cell lymphoma
• * Marginal zone lymphoma (including lymphoma of mucosa-associated tissue \[MALT\])
• * Anaplastic large cell lymphoma
• * Peripheral T-cell lymphoma
• * Cutaneous T-cell lymphoma
• * T/NK cell lymphoma
• * Angioimmunoblastic lymphadenopathy-type T-cell lymphoma
• * Burkitt's lymphoma NOTE: \* If histologic confirmation was made at initial diagnosis, confirmation of relapsed or refractory disease can be made by repeat histologic evaluation OR by evidence of regrowth at a site of disease that was previously histologically confirmed
• Relapsed after or refractory to ≥ 2 prior therapeutic regimens OR patient is ineligible to receive potentially curative therapy
• Bidimensionally measurable or evaluable (e.g., bone marrow or infiltrative organ involvement) disease by physical exam or radiographic study
• No suspicion or evidence of lymphomatous meningitis
• PATIENT CHARACTERISTICS:
• Life expectancy ≥ 12 weeks
• ECOG performance status 0-4
• Not pregnant
• Negative pregnancy test
• Fertile patients must use medically prescribed contraception
• Absolute neutrophil count ≥ 1,000/mm\^3\*
• Platelet count ≥ 50,000/mm\^3\*
• Hemoglobin ≥ 8 g/dL\*
• Serum creatinine ≤ 2.0 mg/dL
• Total bilirubin ≤ 2.0 mg/dL\*\*
• Transaminases \< 5 times upper limit of normal\*\*
• No other malignancy within the past 5 years other than curatively treated non-metastatic skin cancer or in situ cervical carcinoma
• No history of significant or symptomatic cardiac arrhythmia
• No history of myocardial infarction
• No significant ventricular conduction abnormality by ECG or Holter monitoring, as evidenced by any of the following:
• * Prior myocardial infarction
• * Three or more premature ventricular contractions in a row
• No history of pancreatitis
• No history of recent gastrointestinal bleeding
• * Must have heme-negative stool at enrollment NOTE: \*Cytopenias due to direct lymphomatous involvement allowed
• NOTE: \*\*Elevated due to direct lymphomatous involvement allowed
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• More than 3 weeks since prior chemotherapy
• Recovered from prior chemotherapy (alopecia or anemia allowed)
• More than 3 weeks since prior investigational drugs
• No prophylactic antiemetics during course 1
• No other concurrent investigational drugs